N2,N4-bis(indazolin-5-yl)-5-fluoro-2,4-pyrimidinediamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N2,N4-bis(indazolin-5-yl)-5-fluoro-2,4-pyrimidinediamine
• 英文别名: 5-fluoro-2-N,4-N-bis(1H-indazol-5-yl)pyrimidine-2,4-diamine
• 化学式: C₁₈H₁₃FN₈
• 分子量: 360.353
• InChiKey: KFIHLBCPJQNNER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Singh Rajinder

  公开号：US20150266828A1

  公开（公告）日：2015-09-24

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联反应的2,4-嘧啶二胺化合物，该级联反应导致化学介质的释放，以及合成这些化合物的中介体和方法，以及在多种情况下使用这些化合物的方法，包括在治疗和预防由脱粒和其他由IgE和/或IgG受体信号级联反应激活引起的化学介质释放所表征、引起或相关的疾病。
• 2,4-Pyrimidinediamine compounds and their uses
  申请人：Singh Rajinder

  公开号：US20050209230A1

  公开（公告）日：2005-09-22

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联导致释放化学介质的2,4-嘧啶二胺化合物，以及合成这些化合物的中间体和方法，以及在各种情境下使用这些化合物的方法，包括在治疗和预防通过去颗粒化和其他通过激活IgE和/或IgG受体信号级联引起化学介质释放的疾病中。
• 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
  申请人：SINGH Rajinder

  公开号：US20070293521A1

  公开（公告）日：2007-12-20

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联，从而导致化学介质释放的2,4-嘧啶二胺化合物，以及合成该化合物的中间体和方法，以及在各种情况下使用该化合物的方法，包括在通过去颗粒化和其他由IgE和/或IgG受体信号级联的激活引起的化学介质释放所表征，引起或与之相关的疾病的治疗和预防。
• 2,4-Pyrimidinediamine Compounds and their Uses
  申请人：SINGH Rajinder

  公开号：US20110144330A1

  公开（公告）日：2011-06-16

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了能够抑制IgE和/或IgG受体信号级联，从而导致化学介质释放的2,4-嘧啶二胺化合物，以及合成这些化合物的中间体和方法，以及在各种情况下使用这些化合物的方法，包括在通过去颗粒化和其他由IgE和/或IgG受体信号级联激活的过程引起的、由化学介质释放所表征、引起或相关的疾病的治疗和预防。
• Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2130541A2

  公开（公告）日：2009-12-09

  The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

  本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫性疾病的方法，以及治疗、预防或改善与此类疾病相关的症状的方法。可使用本发明化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状、系统性红斑狼疮和/或其相关症状以及多发性硬化症和/或其相关症状。